HUMAN THERAPEUTIC AGENTS
Human therapeutic treatment compositions comprising a curcumin component, a harmine component, and an isovanillin component, preferably all three in combination. The agents are synergistically effective for treatment of human conditions, especially human cancers, such as brain or central nervous system lymphomas or tumors.
1 . A method of treating a patient suffering from a brain or central nervous system lymphoma or tumor, comprising the step of administering to the patient an anticancer composition comprising a combination of synergistically effective amounts of at least one curcumin component comprising curcumin, at least one harmine component comprising harmine, and at least one isovanillin component comprising isovanillin, wherein the components of the composition are different.
2 . The method of claim 1 , wherein said curcumin is synthetically derived or derived from naturally occurring product(s) containing said curcumin which have been treated so that the curcumin is present at a level of at least about 25% by weight in the treated, curcumin-containing naturally occurring product(s), said harmine is synthetically derived or derived from naturally occurring product(s) containing said harmine which have been treated so that the harmine is present at a level of at least about 25% by weight in the treated, harmine-containing naturally occurring product(s), and said isovanillin is synthetically derived or derived from naturally occurring product(s) containing said isovanillin which have been treated so that the isovanillin is present at a level of at least about 25% by weight in the treated, isovanillin-containing naturally occurring product(s).
3 . The method of claim 1 , wherein said curcumin, said harmine, and said isovanillin are each at least about 50% pure.
4 . The method of claim 1 , wherein said isovanillin is present in an amount greater than the amounts of the harmine and the curcumin.
5 . The method of claim 1 , wherein the ratio of said at least one curcumin component, said at least one harmine component, and said at least one isovanillin component is from about 0.1-5:0.1-5:0.1-25.
6 . The method of claim 1 , wherein the at least one isovanillin component is present at a level of from about 25-85% by weight, the at least one harmine component is present at a level of from about 7-50% by weight, and the at least one curcumin component is present at a level of from about 5-40% by weight, based upon the total weight of the three components taken as 100% by weight.
7 . The method of claim 1 , wherein said at least one curcumin component consists essentially of curcumin, said at least one harmine component consists essentially of harmine, and said at least one isovanillin component consists essentially of isovanillin.
8 . The method of claim 1 , wherein said brain or central nervous system lymphoma or tumor is selected from the group consisting of Brain Stem Glioma, Neuroblastoma, Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Astrocytomas, Craniopharyngioma, Ependymoblastoma, Ependymoma, Medulloblastoma, Medulloepithelioma, Pineal Parenchymal Tumors of Intermediate Differentiation, Supratentorial Primitive Neuroectodermal Tumors, Pineoblastoma, Spinal Cord Tumors, and Craniopharyngioma.